{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:33:12Z","timestamp":1786980792741,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T00:00:00Z","timestamp":1628035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T00:00:00Z","timestamp":1628035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["261201000029C"],"award-info":[{"award-number":["261201000029C"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA148143"],"award-info":[{"award-number":["P50 CA148143"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA148143"],"award-info":[{"award-number":["P50 CA148143"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA148143"],"award-info":[{"award-number":["P50 CA148143"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["261201000033C"],"award-info":[{"award-number":["261201000033C"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["Cancer Center Support Grant 2 P30 CA118100-11"],"award-info":[{"award-number":["Cancer Center Support Grant 2 P30 CA118100-11"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["Cancer Center Support Grant 2 P30 CA118100-11"],"award-info":[{"award-number":["Cancer Center Support Grant 2 P30 CA118100-11"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["Cancer Center Support Grant 2 P30 CA118100-11"],"award-info":[{"award-number":["Cancer Center Support Grant 2 P30 CA118100-11"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["Contract HHSN261201800014I, Task Order HHSN26100001"],"award-info":[{"award-number":["Contract HHSN261201800014I, Task Order HHSN26100001"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["3R01CA189184-04S1"],"award-info":[{"award-number":["3R01CA189184-04S1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T32CA09168"],"award-info":[{"award-number":["T32CA09168"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["BC112721"],"award-info":[{"award-number":["BC112721"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Causes Control"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s10552-021-01485-3","type":"journal-article","created":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T06:03:23Z","timestamp":1628057003000},"page":"1375-1384","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Antihypertensive medications and risks of recurrence and mortality in luminal, triple-negative, and HER2-overexpressing breast cancer"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8302-3157","authenticated-orcid":false,"given":"Nicole C.","family":"Lorona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda S.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Tzu C.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre A.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Wiggins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher I.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,4]]},"reference":[{"key":"1485_CR1","unstructured":"Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS) (2017) National Health and Nutrition Examination Survey Data. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. https:\/\/www.cdc.gov\/nchs\/"},{"issue":"3","key":"1485_CR2","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10549-013-2654-3","volume":"140","author":"E Botteri","year":"2013","unstructured":"Botteri E, Munzone E, Rotmensz N et al (2013) Therapeutic effect of beta-blockers in triple-negative breast cancer in postmenopausal women. Breast Cancer Res Treat 140(3):567\u2013575","journal-title":"Breast Cancer Res Treat"},{"issue":"19","key":"1485_CR3","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1200\/JCO.2010.33.4441","volume":"29","author":"A Melhem-Bertrandt","year":"2011","unstructured":"Melhem-Bertrandt A, Chavez-MacGregor M, Lei X et al (2011) Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29(19):2645\u20132652","journal-title":"J Clin Oncol"},{"issue":"11","key":"1485_CR4","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1158\/1055-9965.EPI-17-0346","volume":"26","author":"L Chen","year":"2017","unstructured":"Chen L, Chubak J, Boudreau DM, Barlow WE, Weiss NS, Li CI (2017) Use of antihypertensive medications and risk of adverse breast cancer outcomes in a SEER-medicare population. Cancer Epidemiol Biomarkers Prev 26(11):1603\u20131610","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"1485_CR5","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s10549-014-2870-5","volume":"144","author":"DM Boudreau","year":"2014","unstructured":"Boudreau DM, Yu O, Chubak J et al (2014) Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer. Breast Cancer Res Treat 144(2):405\u2013416","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"1485_CR6","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3109\/07357907.2011.616252","volume":"29","author":"YK Chae","year":"2011","unstructured":"Chae YK, Valsecchi ME, Kim J, Bianchi AL, Khemasuwan D, Desai A, Tester W (2011) Reduced risk of breast cancer recurrence in patients using ACE inhibitors. ARBs and\/or statins Cancer Invest 29(9):585\u2013593","journal-title":"ARBs and\/or statins Cancer Invest"},{"issue":"18","key":"1485_CR7","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1200\/JCO.2012.43.9190","volume":"31","author":"GV S\u00f8rensen","year":"2013","unstructured":"S\u00f8rensen GV, Ganz PA, Cole SW et al (2013) Use of \u03b2-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study. J Clin Oncol 31(18):2265\u20132272","journal-title":"J Clin Oncol"},{"issue":"7","key":"1485_CR8","doi-asserted-by":"publisher","first-page":"628","DOI":"10.18632\/oncotarget.197","volume":"1","author":"DG Powe","year":"2010","unstructured":"Powe DG, Voss MJ, Z\u00e4nker KS et al (2010) Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1(7):628\u2013638","journal-title":"Oncotarget"},{"issue":"2","key":"1485_CR9","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10549-011-1505-3","volume":"129","author":"PA Ganz","year":"2011","unstructured":"Ganz PA, Habel LA, Weltzien EK, Caan BJ, Cole SW (2011) Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat 129(2):549\u2013556","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1485_CR10","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/ijc.30062","volume":"139","author":"S Raimondi","year":"2016","unstructured":"Raimondi S, Botteri E, Munzone E, Cipolla C, Rotmensz N, DeCensi A, Gandini S (2016) Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: systematic review and meta-analysis. Int J Cancer 139(1):212\u2013219","journal-title":"Int J Cancer"},{"issue":"8","key":"1485_CR11","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1093\/annonc\/mdx264","volume":"28","author":"G Spera","year":"2017","unstructured":"Spera G, Fresco R, Fung H, Dyck JRB, Pituskin E, Paterson I, Mackey JR (2017) Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE\/TRIO-012 study. Ann Oncol 28(8):1836\u20131841","journal-title":"Ann Oncol"},{"issue":"1","key":"1485_CR12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1365-2125.2011.03980.x","volume":"72","author":"SM Shah","year":"2011","unstructured":"Shah SM, Carey IM, Owen CG, Harris T, Dewilde S, Cook DG (2011) Does \u03b2-adrenoceptor blocker therapy improve cancer survival? Findings from a population-based retrospective cohort study. Br J Clin Pharmacol 72(1):157\u2013161","journal-title":"Br J Clin Pharmacol"},{"key":"1485_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1741-7015-12-28","volume":"12","author":"CR Cardwell","year":"2014","unstructured":"Cardwell CR, Mc Menamin \u00daC, Hicks BM, Hughes C, Cantwell MM, Murray LJ (2014) Drugs affecting the renin-angiotensin system and survival from cancer: a population based study of breast, colorectal and prostate cancer patient cohorts. BMC Med 12:28","journal-title":"BMC Med"},{"issue":"3","key":"1485_CR14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/EDE.0000000000000814","volume":"29","author":"J Busby","year":"2018","unstructured":"Busby J, Mills K, Zhang SD, Liberante FG, Cardwell CR (2018) Postdiagnostic calcium channel blocker use and breast cancer mortality: a population-based cohort study. Epidemiology 29(3):407\u2013413","journal-title":"Epidemiology"},{"issue":"6","key":"1485_CR15","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1093\/ije\/dyt196","volume":"42","author":"CR Cardwell","year":"2013","unstructured":"Cardwell CR, Coleman HG, Murray LJ, Entschladen F, Powe DG (2013) Beta-blocker usage and breast cancer survival: a nested case-control study within a UK clinical practice research datalink cohort. Int J Epidemiol 42(6):1852\u20131861","journal-title":"Int J Epidemiol"},{"issue":"2","key":"1485_CR16","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s10549-013-2553-7","volume":"139","author":"MD Holmes","year":"2013","unstructured":"Holmes MD, Hankinson SE, Feskanich D, Chen WY (2013) Beta blockers and angiotensin-converting enzyme inhibitors\u2019 purported benefit on breast cancer survival may be explained by aspirin use. Breast Cancer Res Treat 139(2):507\u2013513","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"1485_CR17","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.3892\/or.2016.4710","volume":"35","author":"C Choy","year":"2016","unstructured":"Choy C, Raytis JL, Smith DD et al (2016) Inhibition of \u03b22- Adrenergic receptor reduces triple-negative breast cancer brain metastases: the potential benefit of perioperative \u03b2-blockade. Oncol Rep 35(6):3135\u20133142. https:\/\/doi.org\/10.3892\/or.2016.4710","journal-title":"Oncol Rep"},{"key":"1485_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-016-0299-0","author":"E Pera","year":"2016","unstructured":"Pera E, Kaemmerer E, Milevskiy MJG et al (2016) The voltage gated Ca2+-channel Cav3.2 and therapeutic responses in breast cancer. Cancer Cell Int. https:\/\/doi.org\/10.1186\/s12935-016-0299-0","journal-title":"Cancer Cell Int"},{"key":"1485_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102646","volume":"52","author":"N Kanwar","year":"2020","unstructured":"Kanwar N, Carmine-Simmen K, Nair R et al (2020) Amplification of a calcium channel subunit CACNG4 increases breast cancer metastasis. EBioMedicine 52:102646. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102646","journal-title":"EBioMedicine"},{"key":"1485_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.12.006","author":"S O\u2019Grady","year":"2019","unstructured":"O\u2019Grady S, Morgan MP (2019) Calcium transport and signalling in breast cancer: functional and prognostic significance. Semin Cancer Biol. https:\/\/doi.org\/10.1016\/j.semcancer.2019.12.006","journal-title":"Semin Cancer Biol"},{"key":"1485_CR21","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-15-1104","author":"L Chen","year":"2016","unstructured":"Chen L, Li CI, Tang MTC et al (2016) Reproductive factors and risk of luminal, HER2-overexpressing and triple negative breast cancer among multiethnic women. Cancer Epidemiol Biomarkers Prev. https:\/\/doi.org\/10.1158\/1055-9965.EPI-15-1104","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"20","key":"1485_CR22","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1093\/jnci\/djq366","volume":"102","author":"N Howlader","year":"2010","unstructured":"Howlader N, Ries LA, Mariotto AB, Reichman ME, Ruhl J, Cronin KA (2010) Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst 102(20):1584\u20131598. https:\/\/doi.org\/10.1093\/jnci\/djq366","journal-title":"J Natl Cancer Inst"},{"key":"1485_CR23","doi-asserted-by":"crossref","unstructured":"van Buuren S, Groothuis-Oudshoorn K (2011) mice: Multivariate Imputation by Chained Equations in R. J Stat Softw 45(3):1\u201367. https:\/\/www.jstatsoft.org\/v45\/i03\/","DOI":"10.18637\/jss.v045.i03"},{"key":"1485_CR24","unstructured":"Herman LL, Padala SA, Bashir K (2020) Angiotensin Converting Enzyme Inhibitors (ACEI). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK431051\/"},{"issue":"40","key":"1485_CR25","doi-asserted-by":"publisher","first-page":"7103","DOI":"10.2174\/13816128113199990508","volume":"19","author":"K Regulska","year":"2013","unstructured":"Regulska K, Stanisz B, Regulski M (2013) The renin-angiotensin system as a target of novel anticancer therapy. Curr Pharm Des 19(40):7103\u20137125. https:\/\/doi.org\/10.2174\/13816128113199990508","journal-title":"Curr Pharm Des"},{"issue":"7440","key":"1485_CR26","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1136\/bmj.328.7440.634","volume":"328","author":"B Williams","year":"2004","unstructured":"Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, Thom SM (2004) British hypertension society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 328(7440):634\u2013640","journal-title":"BMJ"},{"issue":"3","key":"1485_CR27","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0895-7061(00)01266-8","volume":"14","author":"TO Morgan","year":"2001","unstructured":"Morgan TO, Anderson AI, MacInnis RJ (2001) ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens 14(3):241\u2013247","journal-title":"Am J Hypertens"},{"issue":"1","key":"1485_CR28","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/1097-0142(20000701)89:1<165::aid-cncr21>3.0.co;2-g","volume":"89","author":"HT S\u00f8rensen","year":"2000","unstructured":"S\u00f8rensen HT, Olsen JH, Mellemkjaer L et al (2000) Cancer risk and mortality in users of calcium channel blockers. A cohort study Cancer 89(1):165\u2013170. https:\/\/doi.org\/10.1002\/1097-0142(20000701)89:1%3c165::aid-cncr21%3e3.0.co;2-g","journal-title":"A cohort study Cancer"},{"key":"1485_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1579","author":"JH Shih","year":"2020","unstructured":"Shih JH, Kao LT, Chung CH et al (2020) Protective association between calcium channel blocker use and breast cancer recurrence in postsurgical women: a population-based case-control study in Taiwan. J Clin Pharmacol. https:\/\/doi.org\/10.1002\/jcph.1579","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"1485_CR30","doi-asserted-by":"publisher","first-page":"e113649","DOI":"10.1371\/journal.pone.0113649","volume":"9","author":"Dong-Qing Guo","year":"2014","unstructured":"Guo Dong-Qing, Zhang Hao, Tan Sheng-Jiang, Gu Yu-Chun (2014) Nifedipine promotes the proliferation and migration of breast cancer cells. PLoS ONE 9(12):e113649. https:\/\/doi.org\/10.1371\/journal.pone.0113649","journal-title":"PLoS ONE"},{"key":"1485_CR31","unstructured":"McKeever RG, Hamilton RJ (2019) Calcium channel blockers. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482473\/"},{"key":"1485_CR32","doi-asserted-by":"publisher","first-page":"e13297","DOI":"10.1038\/ncomms13297","volume":"7","author":"G Jacquemet","year":"2016","unstructured":"Jacquemet G, Baghirov H, Georgiadou M et al (2016) L-type calcium channels regulate filopodia stability and cancer cell invasion downstream of integrin signalling. Nat Commun 7:e13297. https:\/\/doi.org\/10.1038\/ncomms13297","journal-title":"Nat Commun"},{"issue":"25","key":"1485_CR33","doi-asserted-by":"publisher","first-page":"11405","DOI":"10.1073\/pnas.0911186107","volume":"107","author":"J VanHouten","year":"2010","unstructured":"VanHouten J, Sullivan C, Bazinet C et al (2010) PMCA2 regulates apoptosis during mammary gland involution and predicts outcome in breast cancer. Proc Natl Acad Sci U S A 107(25):11405\u201311410. https:\/\/doi.org\/10.1073\/pnas.0911186107","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"1485_CR34","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1200\/JCO.2010.33.5422","volume":"29","author":"TI Barron","year":"2011","unstructured":"Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K (2011) Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol 29(19):2635\u20132644","journal-title":"J Clin Oncol"},{"issue":"5","key":"1485_CR35","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1158\/1078-0432.CCR-11-0641","volume":"18","author":"SW Cole","year":"2012","unstructured":"Cole SW, Sood AK (2012) Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res 18(5):1201\u20131206","journal-title":"Clin Cancer Res"},{"issue":"27","key":"1485_CR36","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000168","volume":"93","author":"J V\u00e1clav\u00edk","year":"2014","unstructured":"V\u00e1clav\u00edk J, Vyso\u010danov\u00e1 P, Seidlerov\u00e1 J et al (2014) Reasons for switching antihypertensive medication in general practice: a cross-sectional Czech nationwide survey. Medicine (Baltimore) 93(27):e168. https:\/\/doi.org\/10.1097\/MD.0000000000000168","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"1485_CR37","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/jnci\/djq091","volume":"102","author":"ML Maitland","year":"2010","unstructured":"Maitland ML, Bakris GL, Black HR et al (2010) Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 102(9):596\u2013604. https:\/\/doi.org\/10.1093\/jnci\/djq091","journal-title":"J Natl Cancer Inst"}],"container-title":["Cancer Causes &amp; Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-021-01485-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10552-021-01485-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-021-01485-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T04:31:11Z","timestamp":1635222671000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10552-021-01485-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,4]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1485"],"URL":"https:\/\/doi.org\/10.1007\/s10552-021-01485-3","relation":{},"ISSN":["0957-5243","1573-7225"],"issn-type":[{"value":"0957-5243","type":"print"},{"value":"1573-7225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,4]]},"assertion":[{"value":"3 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The institutional review boards at the Fred Hutchinson Cancer Research Center and University of New Mexico approved this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}